| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
β-Amyrone targets multiple biological pathways. It inhibits COX-2 expression, which is responsible for its anti-inflammatory activity. It also exhibits anti-α-glucosidase inhibitory activity and moderate anti-acetylcholinesterase (AChE) activity. These diverse activities suggest interactions with multiple targets, including enzymes involved in inflammation, carbohydrate metabolism, and neurotransmission.
|
|---|---|
| ln Vitro |
β-Amyrone (1.25-10 μg/mL, 24 h) has no appreciable influence on cell survival and suppresses the generation of NO∙ in LPS-stimulated J774 cells with an IC50 value of 4.61 μg/mL [1]. β-Amyrone (10 μg/mL, 24 hours) suppresses COX-2 expression, IL-6, and IL-10 levels in J774 cells treated with lipopolysaccharide [1]. With an EC50 value of 86 uM, β-Amyrone (0-235 μM, 7 days) exhibits antiviral activity against the chikungunya virus (CHIKV) in Vero cells. With IC50 values of 25 μM, 23 μM, and 8 μg/mL, respectively, β-amyrone inhibits the activity of α-glucosidase, acetylcholinesterase (AChE), and fungal growth [4].
In vitro, β-Amyrone exhibits anti-α-glucosidase inhibitory activity and moderate anti-acetylcholinesterase (AChE) activity. It also shows antifungal activity. Specific IC50 values for these activities are not provided in the available sources. Its anti-inflammatory activity is mediated through inhibition of COX-2 expression. |
| ln Vivo |
β-Amyrone (topical injection to the ear, 0.1-0.6 mg/kg, single dose) reduces the production of ear edema in mice with phenol-induced edema [1].
In vivo, β-Amyrone has anti-inflammatory activity. It also exhibits antiviral activity against Chikungunya virus. Specific in vivo efficacy data, such as dosing regimens and outcome measures, are not provided in the available sources. |
| Enzyme Assay |
A cell-free assay for β-Amyrone would involve measuring its inhibition of α-glucosidase or acetylcholinesterase enzymatic activity. In these assays, the enzyme is incubated with a substrate in the presence of varying concentrations of the compound, and the rate of substrate conversion is measured. Its anti-inflammatory activity can be assessed by measuring COX-2 inhibition. Specific protocols are not detailed.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: LPS (1 μg/mL) Stimulated J774 cell Tested Concentrations: 2.5, 5, 10 μg/mL Incubation Duration: 24 h Experimental Results: Inhibition of COX-2 expression in a concentration-dependent manner (approximately 5 or 90% reduction at 10 μg/mL). Cellular assays for β-Amyrone would typically involve assessing its effects on inflammation, such as measuring COX-2 expression or cytokine production in treated cells. Its antiviral activity can be assessed in virus-infected cells. Specific protocols are not detailed. |
| Animal Protocol |
Animal/Disease Models: Balb C mouse otophenol-induced edema [1]
Doses: 0.1, 0.3, 0.6 mg/kg, single dose Route of Administration: local administration to the ear (20 𝜇L solution) Experimental Results: Inhibition of ear edema formation by dose Related methods (inhibition rate at 0.6 mg/kg Doses: 47%). In vivo animal experiments for β-Amyrone are not described in the available sources. As a naturally occurring compound with anti-inflammatory and antiviral activities, it could be evaluated in animal models of inflammation or viral infection. However, no specific protocols or data are provided. |
| ADME/Pharmacokinetics |
β-Amyrone has a molecular formula of C30H48O. It is a naturally occurring pentacyclic triterpenoid. Specific pharmacokinetic parameters are not provided in the available sources. The compound is typically isolated from plant sources for research purposes.
|
| Toxicity/Toxicokinetics |
Toxicity data for β-Amyrone are not provided in the available sources. As a naturally occurring compound, it may have a favorable safety profile, but no specific toxicological information is available. The compound is intended for research use only and not for human consumption.
|
| References |
|
| Additional Infomation |
β-Amyrone has reportedly been found in Erythrophleum fordii, Lepidaploa myriocephala, and other organisms with available data.
β-Amyrone (CAS: 638-97-1) is a naturally occurring pentacyclic triterpenoid. It is also known as β-Amyron and β-Amyrenone. The compound has anti-inflammatory activity through inhibition of COX-2 expression, as well as antifungal, anti-α-glucosidase, anti-acetylcholinesterase, and antiviral activities. Its molecular formula is C30H48O. It is not an approved drug and is strictly for research purposes. |
| Molecular Formula |
C30H48O
|
|---|---|
| Molecular Weight |
424.70152
|
| Exact Mass |
424.37
|
| CAS # |
638-97-1
|
| PubChem CID |
12306160
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
488.3±45.0 °C at 760 mmHg
|
| Flash Point |
202.8±23.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
10.48
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
31
|
| Complexity |
831
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCC(=O)C5(C)C)C)C)[C@@H]1CC(CC2)(C)C)C
|
| InChi Key |
LIIFBMGUDSHTOU-CFYIDONUSA-N
|
| InChi Code |
InChI=1S/C30H48O/c1-25(2)15-16-27(5)17-18-29(7)20(21(27)19-25)9-10-23-28(6)13-12-24(31)26(3,4)22(28)11-14-30(23,29)8/h9,21-23H,10-19H2,1-8H3/t21-,22-,23+,27+,28-,29+,30+/m0/s1
|
| Chemical Name |
(4aR,6aR,6bS,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-2,4a,5,6,7,8,9,10,12,12a,14,14a-dodecahydro-1H-picen-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3546 mL | 11.7730 mL | 23.5460 mL | |
| 5 mM | 0.4709 mL | 2.3546 mL | 4.7092 mL | |
| 10 mM | 0.2355 mL | 1.1773 mL | 2.3546 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
